HC Wainwright Analysts Decrease Earnings Estimates for PRAX

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Stock analysts at HC Wainwright decreased their Q2 2025 earnings estimates for shares of Praxis Precision Medicines in a research report issued to clients and investors on Monday, May 5th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($3.83) for the quarter, down from their prior estimate of ($3.64). HC Wainwright has a “Buy” rating and a $105.00 price target on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q3 2025 earnings at ($4.28) EPS, Q4 2025 earnings at ($4.29) EPS, FY2025 earnings at ($15.69) EPS, FY2026 earnings at ($19.37) EPS, FY2027 earnings at ($17.34) EPS and FY2028 earnings at ($7.95) EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%.

A number of other brokerages have also issued reports on PRAX. Needham & Company LLC restated a “buy” rating and issued a $80.00 price target on shares of Praxis Precision Medicines in a research note on Monday. Truist Financial dropped their target price on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Wedbush lifted their target price on Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an “underperform” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Praxis Precision Medicines in a report on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price target for the company. Finally, Robert W. Baird lowered their price objective on Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $120.56.

Praxis Precision Medicines Stock Down 9.7 %

PRAX stock opened at $35.17 on Wednesday. The stock’s 50 day moving average is $35.50 and its two-hundred day moving average is $61.55. Praxis Precision Medicines has a 52-week low of $26.70 and a 52-week high of $91.83. The company has a market capitalization of $716.38 million, a PE ratio of -3.41 and a beta of 2.65.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of institutional investors have recently bought and sold shares of PRAX. GF Fund Management CO. LTD. acquired a new position in shares of Praxis Precision Medicines in the fourth quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Praxis Precision Medicines in the 4th quarter valued at approximately $48,000. GAMMA Investing LLC boosted its stake in Praxis Precision Medicines by 6,075.4% in the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company’s stock worth $152,000 after purchasing an additional 3,949 shares during the period. Graham Capital Management L.P. acquired a new position in Praxis Precision Medicines in the 4th quarter worth approximately $209,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Praxis Precision Medicines during the 4th quarter worth approximately $215,000. Hedge funds and other institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.